NCT05701436

Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Applicability of 3D Histoculture Drug Response Assay(3D-HDRA) in Patients With Primary Liver Cancer: A Randomized Controlled Trial

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 144 (estimated)
• Sponsor: Zhujiang Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This Randomized Controlled Trial was to clarity the clinical feasibility of 3D-HDRA results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.

Detailed description

Data of Patients who received 3D-HDRA after primary liver cancer radical reaction and received Transarterial Chemoembolization #will be collected #excluding incomplete data. The primary endpoint was the one-year disease-free survival(DFS) rate #Secondary endpoint was the adverse event.

Conditions

• Liver, Cancer of, Primary Resectable

Interventions

Type	Name	Description
DRUG	Oxaliplatin	130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
DRUG	Doxorubicin	20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
DRUG	Lobaplatin	50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
DRUG	Cisplatin	50 mg per square body surface area was used for monthly transhepatic arterial infusions.
DRUG	Oxaliplatin, Leucovorin, fluorouracil	Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.
DRUG	Lobaplatin, Raltitrexed	Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.

Timeline

• Start date: 2022-09-01
• Primary completion: 2026-01-01
• Completion: 2026-03-01
• First posted: 2023-01-27
• Last updated: 2023-03-02

Locations

1 site across 1 country: China